News | June 28, 2023
Oncodesign Services announce access to ImaginAb’s CD8 ImmunoPET technology
Oncodesign Services and ImaginAb sign a Preclinical License and Supply Agreement
Oncodesign Services and ImaginAb sign a Preclinical License and Supply Agreement
Cullgen will have the option during the initial stages of clinical development to participate equally in the costs, profits and losses
Laurus will also provide funding for the clinical trials and will launch these products in India and emerging markets
Application being reviewed under the FDA Project Orbis framework, which enables concurrent reviews among US, Australia, Canada, Switzerland, Singapore and United Kingdom health authorities
Lantern is receiving an exclusive and worldwide option to license intellectual property from Bielefeld University related to the collaboration and IP generated from the collaboration
Acuitas Therapeutics' LNP technology will support Bayer’s in vivo gene editing and protein replacement programs with the goal of specifically delivering RNA payloads to the desired target organ, the liver.
Acquisition will further strengthen Lonza’s bioconjugates offering through the integration of the industry-leading proprietary Synaffix technology platform and R&D capabilities, including payload and site-specific linker technology
These announcements are in line with Croda Pharma’s strategy to “Empower Biologics Delivery” and follows news on investments, earlier this year, to expand Croda Pharma’s global manufacturing capabilities to enable the next generation vaccines and therapeutic drugs.
Testing supporting allergy diagnosis now accessible to more people in more communities
Nous-209 has been developed using the Nouscom's viral vector platform
Subscribe To Our Newsletter & Stay Updated
